QUREHIGH SIGNALFINANCIAL10-K

QURE underwent a dramatic financial transformation with stockholders' equity swinging from negative $6.8M to positive $198.9M while revenue declined 48% and share count increased 16%.

The massive equity improvement of over 3,000% combined with increased share count suggests a significant equity raise or restructuring that eliminated previous deficits, providing crucial liquidity for this biotech company. However, the sharp revenue decline and quadrupling of interest expense indicate operational challenges and increased debt burden that could pressure future performance.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

QURE's balance sheet strengthened dramatically with stockholders' equity turning positive by $205.7M and total assets growing 48% to $825M, while current assets expanded 68% despite cash declining by half to $80M. The income statement deteriorated significantly with revenue falling 48% to $13.1M and interest expense surging 255% to $42M, suggesting increased debt financing. Capital expenditures plummeted 87%, indicating reduced investment in operations, while the overall picture suggests a company that raised substantial capital to address financial distress but faces mounting operational and financing pressures.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+3045.8%
-$6.8M→$198.9M

Equity base grew 3045.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
+255.1%
$11.7M→$41.6M

Interest expense surged 255.1% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-87%
$3.4M→$439K

Capex reduced 87% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+79.8%
$3.7M→$6.6M

Receivables surged 79.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Inventory
Balance Sheet
+73.7%
$6.9M→$12.0M

Inventory surged 73.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+68.1%
$390.3M→$656.0M

Current assets grew 68.1% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+57.1%
$40.1M→$62.9M

Current liabilities surged 57.1% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-49.5%
$158.9M→$80.2M

Cash declined 49.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
+48.2%
$556.5M→$824.9M

Asset base grew 48.2% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
-47.8%
$25.1M→$13.1M

Revenue declined 47.8% — significant demand weakness or market share loss warrants investigation.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
As of February 26, 2026, the registrant had 62,529,408 ordinary shares, par value 0.05, outstanding.
If we are unable to successfully commercialize our product candidates or experience significant delays in doing so, including as result of a BLA or other key regulatory filings being delayed or rejected, our business could be materially harmed.
Disruptions or changes at the FDA, or other government agencies, as a result of funding cuts, personnel losses, leadership changes, regulatory changes or regulatory reform, government shutdowns and other developments could hinder the timing of or our ability to obtain further guidance from the FDA regarding our clinical development programs and secure approval of our product candidates in a timely manner, which could adversely affect our business.
We may leverage certain specialized regulatory pathways and designations, such as the FDA s accelerated approval pathway, Regenerative Medicine Advance Therapy ( RMAT ) designation and Breakthrough Therapy designation, to develop our product candidates or to seek licensure.
Our business development and strategic initiatives, acquisitions, partnerships, collaborations or other transactions, may not achieve their intended benefits or goals and may result in additional risks to our business.
+7 more — sign up free →
REMOVED
As of February 24, 2025, the registrant had 54,076,880 ordinary shares, par value 0.05, outstanding.
If we are unable to successfully commercialize our product candidates or experience significant delays in doing so, our business could be materially harmed.
We may leverage certain specialized regulatory pathways and designations, such as the FDA s accelerated approval pathway and RMAT designation, to develop our product candidates or to seek licensure.
Our business development and strategic initiatives, including divestitures such as the Lexington Transaction, acquisitions, partnerships, collaborations or other transactions, may not achieve their intended benefits or goals and may result in additional risks to our business.
We may not be successful in obtaining rights from external parties to new product candidates and key technologies, or in securing partnerships to support the development or commercialization of our product candidates.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →